Cosette Pharmaceuticals Acquires Global Rights to Intrarosa from Endoceutics

Cosette Pharmaceuticals Acquires Vyleesi from Palatin Technologies

January 3, 2024

Pharmaceuticals

Cosette Pharmaceuticals, a U.S. specialty pharmaceutical company backed by Avista Healthcare Partners, has acquired the Vyleesi (bremelanotide) product and related intellectual property from Palatin Technologies. The deal transfers five Orange Book-listed patents (protection through 2041) and aims to expand Cosette’s women's health portfolio while ensuring continued patient access during the transition.

Hamilton Lane Acquires Significant Equity Interest in Cosette Pharmaceuticals; Partners with Avista Capital

July 17, 2024

Pharmaceuticals

Funds managed by Hamilton Lane have acquired a significant equity interest in Cosette Pharmaceuticals from Avista Capital Partners and its co-investors. Avista and Hamilton Lane will jointly control Cosette as the company strengthens its balance sheet to accelerate R&D, product innovation and future M&A activity.

Essential Pharma Acquires Yorkdale Pharma from Rosemont; Sells Oral Liquid Portfolio to Rosemont and Buys Two Product Rights from Novartis

December 21, 2021

Pharmaceuticals

Gyrus Capital‑backed Essential Pharma completed a refinancing and executed a series of portfolio transactions in December 2021. Essential Pharma acquired Yorkdale Pharma Limited from Rosemont Pharmaceuticals, divested its 14‑product oral liquid portfolio (Essential Pharma Liquids Limited) to Rosemont, and also acquired worldwide (ex‑US, ex‑India) rights to two products from Novartis to expand its global specialty pharmaceutical portfolio.

Incyte Acquires Escient Pharmaceuticals

April 23, 2024

Biotechnology

Incyte has agreed to acquire Escient Pharmaceuticals for $750 million plus Escient's net cash, adding two first‑in‑class oral MRGPR antagonists (EP262 and EP547) to its inflammation and autoimmunity portfolio. The acquisition, subject to customary closing conditions and HSR clearance, expands Incyte's pipeline in dermatology, chronic urticaria and pruritus with expected closing in 3Q 2024.

Pharmacosmos Acquires G1 Therapeutics

August 7, 2024

Biotechnology

Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.